On Jun. 1, 2020, Entos Pharmaceuticals announced a partnership with Cytiva, formerly part of GE Healthcare Life Sciences. Cytiva will work with Entos to optimize a clinical manufacturing solution for the companyﾒs Covigenix COVID-19 DNA vaccine candidate.

Entos Pharmaceuticals develops next generation nucleic acid medicines using their Fusogenix platform, which uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells.